{
  "id": 6714501,
  "title": "Novartis investors turn spotlight on M&A after trial setbacks",
  "url": "https://urgent.news/2026/09/11/novartis-investors-turn-spotlight-on-m-a-after-trial-setbacks",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-11T05:06:27.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/novartis-investors-turn-spotlight-on-ma-after-trial-setbacks-4897220"
  },
  "original_language": "en",
  "account": "Novartis investors are intensifying their scrutiny of the company's dealmaking strategy in light of setbacks caused by drugs acquired through mergers and acquisitions, which have impacted its shares. The recent failure of muscle-wasting disorder drug del-desiran, which failed in a late-stage study, has raised concerns about the impact of last year's $12 billion Avidity acquisition and other acquisitions. Novartis shares dropped 11% in one day this week, resulting in a loss of nearly $30 billion in market value since the start of the year. CEO Vas Narasimhan, known for his shareholder-friendly record, now faces pressure to outline his plans for steering the company through pending patent expirations. Analysts suggest smaller, bolt-on acquisitions might have been more beneficial than large-scale deals. Despite the setbacks, Novartis still possesses promising drugs like remibrutinib in its pipeline. CEO Narasimhan has committed over $30 billion to acquisitions and partnerships in the last three years but there are no plans to alter the company's approach towards M&A or business development.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}